Certified by Founder
Lodge
BioLoomics, Inc.
start up
United States
- Boulder, CO
- 20/09/2023
- Seed
- $8,700,000
BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create target degrading antibodies. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.
#synbio #directedevolution #antibodies
- Industry Biotechnology Research
- Website https://www.bioloomics.com/
- LinkedIn https://www.linkedin.com/company/bioloomics/about/
Humand | $66,000,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)
Freeform | $67,000,000 | (Feb 24, 2026)
Coral Care | $13,000,000 | (Feb 24, 2026)
Reload | $2,275,000 | (Feb 24, 2026)